Blopress led sluggish Japanese market in 2008
This article was originally published in Scrip
Executive Summary
Takeda's Blopress (candesartan) was again the top-selling prescription drug in Japan last year, although growth for both it and the wider market was constrained by the regular reimbursement price cut in April. This averaged 5.2% and meant that the total market expanded by just 3% to ¥8,254.3 billion ($83.8 billion), compared with growth of around 5% in 2007, an "off year" for the biennial price revision.